Other

Matthew Sills

Joseph P Errico

Benjamin Mugrage

Jane Ong

Ignatius Turchi

John Allocco

Pam Wines

Margarita Bastos

Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.

Combination therapy with MDM2 and EFGR inhibitors

Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

Methods of targeted drug development

Methods and compositions of targeted drug development

Growing community of inventors

Berkeley Heights, NJ, United States of America

Matthew Sills